Trial
NCT04678505
Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Renal Impairment
Intervention
MK-3402
Why stopped
Business reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-04